HBOT resolves radiation cystitis symptoms in roughly 80% of patients, according to the largest systematic review of 815 cases. Complete resolution of bleeding occurred in 34% of patients and significant improvement in another 45%. Outcomes are significantly better when treatment starts within six months of symptom onset, with 96% response rates in early-treatment groups versus lower rates when delayed. It is one of several hyperbaric oxygen therapy for chronic conditions that researchers are actively investigating. This is one of several range of cancer treatment uses for hyperbaric oxygen currently under clinical review.
What Is Radiation Cystitis?
Radiation cystitis develops when the bladder sustains cumulative damage from ionizing radiation used to treat nearby cancers: prostate, cervical, rectal, bladder, and other pelvic malignancies. The damage is not immediate. Radiation causes progressive obliteration of small blood vessels, reducing oxygen delivery to bladder tissue over time. The result is a cascade of injury: mucosal breakdown, fibrosis, and the fragile, abnormally formed blood vessels called telangiectasias that bleed easily.
Symptoms range from mild irritation and urinary frequency to severe hemorrhagic cystitis, where bleeding is heavy enough to cause clots, obstruction, and hospitalization. Conservative treatments (hydration, bladder irrigation, fulguration) often provide temporary relief but do not address the underlying vascular damage. This is where HBOT enters the picture.
How Does HBOT Work for Radiation Cystitis?
The core problem in radiation cystitis is hypoxia in damaged tissue. Blood vessels that have been scarred by radiation can no longer deliver adequate oxygen, which means the tissue cannot heal normally. HBOT directly counteracts this by dissolving high concentrations of oxygen into the plasma, bypassing the damaged hemoglobin-carrying red blood cells and reaching tissue that normal circulation cannot adequately supply.
Beyond acute oxygenation, repeated HBOT sessions trigger angiogenesis: the growth of new blood vessels into the ischemic tissue. This is the mechanism that produces lasting improvement rather than just temporary relief. For a deeper look at how this process works, the HBOT research overview covers the underlying biology in detail.
What Does the Research Say?
Radiation cystitis has more clinical evidence supporting HBOT than almost any other non-standard HBOT application. A 2024 systematic review and meta-analysis of 14 studies with 556 patients found that nearly 90% of radiation cystitis patients experienced symptom improvement with HBOT, with 55% achieving complete remission of hematuria (95% CI 51-59%).1
In the largest systematic review of 815 radiation cystitis patients treated with HBOT, the weighted average overall response rate was 87.3%, with 65.3% achieving complete resolution of symptoms.”
Villeirs et al., 2019
A 2019 systematic review of 20 papers with 815 patients found a weighted average overall response rate of 87.3% and a complete response rate of 65.3%.2 A 2018 meta-analysis of 13 studies and 602 patients found 84% achieved partial or complete resolution, with at least 1-grade hematuria improvement in 75% of patients and a 14% recurrence rate.3
FDA-Cleared Indication
The FDA has cleared HBOT for radiation tissue damage, which includes radiation cystitis. This puts it in a different category from many conditions where HBOT is used experimentally. The Undersea and Hyperbaric Medical Society (UHMS) formally recognizes delayed radiation injury of soft tissue and bone as an approved indication.
Durability of Response
One concern with any treatment for chronic radiation damage is whether improvements last. The RICH-ART trial, with 5-year follow-up data published in 2025, found that 68.6% of responders maintained their gains, with a mean improvement of 22.9 points on patient-reported urinary symptom scores sustained over the long term.9 Recurrence rates across studies are approximately 14%, and repeat HBOT courses have been effective for those who do recur.
Starting HBOT within six months of hematuria onset leads to significantly better outcomes. Of the patients who failed to respond, most had either started treatment late or completed fewer than the recommended number of sessions.”
Chong & Hampson, 2005; Corman et al., 2003
Timing Matters
Research consistently shows that earlier HBOT intervention leads to better outcomes. A landmark study demonstrated that patients who began HBOT within 6 months of developing hematuria had significantly better results than those who waited longer.6 Among non-responders in one major study, the majority had either started treatment late or did not complete the recommended number of sessions.5
Who Is a Candidate?
Best candidates are patients with documented radiation-induced bladder injury who have completed cancer treatment (no active malignancy in the bladder), have not responded adequately to conservative measures, and are medically stable enough to tolerate a pressurized environment. Cystoscopy confirming telangiectasias or mucosal damage from radiation is typically required before referral for HBOT evaluation.
Active bladder cancer is generally a contraindication. Severe untreated emphysema, certain medications (bleomycin, doxorubicin, cisplatin), active ear or sinus disease, and severe claustrophobia are potential barriers. The full side effect and contraindication guide covers what to review with your physician before starting treatment.
What Does the HBOT Protocol Look Like?
The standard protocol for radiation cystitis involves 30 to 40 sessions at pressures between 2.0 and 2.4 ATA. Each session runs approximately 90 minutes, with the patient breathing 100% oxygen through a mask or hood inside a hard-shell chamber. Treatment is typically delivered five days per week, making a full course six to eight weeks. Patients with severe hemorrhagic cystitis may require more sessions.
Some centers use 20 sessions as an initial course and assess response before proceeding. Current evidence suggests a minimum of 30-40 sessions for optimal results. The session guide explains what each visit involves and how to prepare.
Does Insurance Cover HBOT?
Because radiation cystitis is an approved HBOT indication, insurance coverage is significantly more accessible than for off-label uses. Medicare covers HBOT for delayed radiation injury, and most major commercial insurers follow Medicare’s coverage policies for approved indications. Prior authorization is almost always required, and documentation from the treating oncologist or urologist is essential. The HBOT insurance coverage guide walks through the prior authorization process.
What Should You Expect During Treatment?
Most patients with radiation cystitis do not notice dramatic improvement in the first one to two weeks. The angiogenic response that drives healing takes time to build. Many patients report that bleeding frequency and severity begin to decrease around weeks three to four, with continued improvement through the end of the course and for several months afterward as new vessels mature.
In a prospective study of 33 patients published in 2026, 81.8% achieved complete response, 9.1% achieved partial response (combined rate: 90.9%), at a mean of 29.2 sessions. All patients completed treatment without complications and were alive at end of follow-up.4
Radiation Cystitis vs. Other Radiation Injuries
Radiation damage is rarely isolated to the bladder. Patients treated for pelvic cancers often have concurrent radiation proctitis, vaginal or erectile tissue damage, or bone changes in the pelvic region. HBOT’s mechanism is the same across all of these: promoting angiogenesis in ischemic, radiation-damaged tissue. Many patients being treated for radiation cystitis find that other radiation-related symptoms also improve during the course of treatment. The broader topic of radiation damage and HBOT covers the full spectrum of post-radiotherapy applications.
The Role of Cystoscopy in Treatment Planning
Before starting HBOT for radiation cystitis, most hyperbaric programs require documentation of the condition through cystoscopy. This procedure allows the urologist to directly visualize the bladder wall, confirm the presence of radiation-induced telangiectasias or mucosal damage, and rule out recurrent or new malignancy. Cystoscopy findings also help stage the severity of radiation cystitis, which informs prognosis and sets realistic expectations for HBOT response.
What Happens If HBOT Partially Works
Not every patient achieves complete resolution after one course of HBOT. Partial responders may benefit from additional sessions or a repeat course after a period of clinical evaluation. Some centers offer “booster” protocols of 10 to 20 additional sessions. The angiogenic mechanism does not have a strict ceiling on how many times it can be stimulated, and tissue vascularity can continue to improve with additional treatment.
Finding a Qualified Facility
Radiation cystitis treatment should be delivered in a hospital-based or accredited outpatient hyperbaric facility, not a wellness spa or mild HBOT center. The pressures required (2.0+ ATA) for therapeutic effect can only be safely achieved in hard-shell monoplace or multiplace chambers certified for medical use. UHMS accreditation is a useful marker of quality. Your oncologist or urologist should be able to provide a referral to an accredited facility.
Frequently Asked Questions
How many HBOT sessions does radiation cystitis typically require?
Most protocols involve 30 to 40 sessions. Some patients show adequate response after 20 sessions; others with severe or long-standing damage may need up to 60. Your hyperbaric physician will assess response during treatment and adjust the course accordingly.
How long after radiation therapy can HBOT still help?
HBOT can help even when radiation cystitis develops years after treatment. The mechanism (promoting angiogenesis in chronically ischemic tissue) is not time-limited. Studies include patients treated a decade or more after their radiation therapy.
Will HBOT cure radiation cystitis completely?
Many patients achieve complete resolution of bleeding and significant improvement in bladder symptoms. A proportion experience partial improvement. A minority do not respond. Complete response rates across meta-analyses range from 55-65%. Realistic expectations should be set before starting treatment based on the severity and chronicity of symptoms.
Is HBOT safe if my cancer is not fully in remission?
Active cancer in the treatment area is generally a contraindication for HBOT, as oxygen may theoretically support tumor growth. A recent clear scan and oncologist sign-off are standard requirements before starting treatment for radiation injuries.
Can I have HBOT and continue other bladder treatments?
In most cases, yes. HBOT is typically used alongside rather than instead of other treatments. Your hyperbaric team will coordinate with your urologist and oncologist to ensure there are no conflicts.
References
- Yang TK, et al. Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis: A Systematic Review and Meta-Analysis. J Clin Med. 2024;13(16):4724. DOI: 10.3390/jcm13164724. PMID: 39200867.
- Villeirs L, et al. Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy: Systematic review of the recent literature. Int J Urol. 2019;26(12):1145-1156. DOI: 10.1111/iju.14130. PMID: 31617263.
- Cardinal JR, et al. Scoping Review and Meta-analysis of Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis. Curr Urol Rep. 2018;19(9):79. DOI: 10.1007/s11934-018-0790-3. PMID: 29654564.
- Chairetakis G, et al. Hyperbaric oxygen therapy in the management of radiation-induced hemorrhagic cystitis: a prospective study. Hellenic Urol. 2026. DOI: 10.23736/s2241-9136.25.00103-3.
- Corman JM, et al. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen. J Urol. 2003;169(6):2200-2202. DOI: 10.1097/01.JU.0000063640.41307.C9. PMID: 12771749.
- Chong KT, Hampson NB, Corman JM. Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology. 2005;65(4):649-653. DOI: 10.1016/j.urology.2004.10.050. PMID: 15833500.
- Shilo Y, et al. Hyperbaric oxygen for hemorrhagic radiation cystitis. Isr Med Assoc J. 2013;15(2):75-78. PMID: 23516766.
- Lin KH, et al. Hyperbaric oxygen therapy for hemorrhagic radiation cystitis. Formosan J Surg. 2017;50(3):104-109. DOI: 10.4103/fjs.fjs_19_17.
- RICH-ART Trial 5-Year Follow-Up. PMC12033922. 2025. Patient-reported urinary symptom improvements sustained over 5 years; 68.6% of responders maintained benefit.
- Oliai C, et al. Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis. Int J Radiat Oncol Biol Phys. 2012;83(3):e475-9. DOI: 10.1016/j.ijrobp.2011.12.056. PMID: 22440041.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
